Fecal microbiome in systemic sclerosis,in search for the best candidate for microbiota-targeted therapy for small intestinal bacterial overgrowth control
Restricted accessEditorialFirst published online October, 2022
Fecal microbiome in systemic sclerosis,in search for the best candidate for microbiota-targeted therapy for small intestinal bacterial overgrowth control
Gastrointestinal involvement is a common complication in systemic sclerosis patients and must be suspected and investigated already in the early stages of the disease. Gastrointestinal symptoms and complications—such as gastroesophageal reflux disease, intestinal pseudo-obstruction, malnutrition, diarrhea, constipation, and small intestinal bacterial overgrowth—severely impair systemic sclerosis patients’ quality of life and affect their prognosis. Although some pathogenetic aspects of the gastrointestinal involvement in systemic sclerosis remain unclear, defining the characteristics of the microbiota and its role could help in risk stratification, selection of candidates for microbiota-targeted therapies, prediction of standard treatment efficacy, and prognosis of systemic sclerosis patients. Finally, understanding how to modify the microbiota composition may represent an important therapeutic approach to target gastrointestinal involvement in systemic sclerosis.
KumarSSSinghJRattanS, et al. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment Pharmacol Ther2017; 45(7): 883–898.
2.
KumarSSinghJKedikaR, et al. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. Am J Physiol Gastrointest Liver Physiol2016; 310(11): G1052–G1060.
3.
RussoEETaddeiARingressiMN, et al. The interplay between the microbiome and the adaptive immune response in cancer development. Therap Adv Gastroenterol2016; 9(4): 594–605.
4.
FengXXLiXQJiangZ. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol2021; 40(8): 3039–3051.
5.
PimentelMSaadRJLongMD, et al. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol2020; 115(2): 165–178.
6.
PittmanNRawnSMWangM, et al. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology2018; 57(10): 1802–1811.
7.
VolkmannERERVargaJ. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol2019; 15(4): 208–224.
8.
KhannaDDNagarajaVGladueH, et al. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol2013; 25(6): 700–706.
9.
RussoEEBacciGChielliniC, et al. Preliminary comparison of oral and intestinal human microbiota in patients with colorectal cancer: a pilot study. Front Microbiol2017; 8: 2699.
10.
SartorRBRB. Microbial influences in inflammatory bowel diseases. Gastroenterology2008; 134(2): 577–594.
11.
HeviaAMilaniCLópezP, et al. Intestinal dysbiosis associated with systemic lupus erythematosus. mBio2014; 5(5): e01548-14.
12.
MukhopadhyaIHansenREl-OmarEM, et al. IBD—What role do Proteobacteria play. Nat Rev Gastroenterol Hepatol2012; 9(4): 219–230.
13.
RussoEGiudiciFRicciF, et al. Diving into inflammation: a pilot study exploring the dynamics of the immune-microbiota axis in ileal tissue layers of patients with Crohn’s disease. J Crohns Colitis2021; 15(9): 1500–1516.
14.
CostelloM-EMECicciaFWillnerD, et al. Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol2015; 67(3): 686–691.
15.
GeversDKugathasanSDensonLA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe2014; 15(3): 382–392.
16.
DeyNSoergelDARepoS, et al. Association of gut microbiota with post-operative clinical course in Crohn’s disease. BMC Gastroenterol2013; 13(1): 131.
17.
BellocchiCVolkmannER. Update on the gastrointestinal microbiome in systemic sclerosis. Curr Rheumatol Rep2018; 20(8): 49.
18.
SinghJJCohenSMehendirattaV, et al. Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. Gastroenterology2012; 143(5): 1308–1318.
19.
Kowal-BieleckaOOFransenJAvouacJ, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis2017; 76(8): 1327–1339.
20.
SuTTLaiSLeeA, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol2018; 53(1): 27–36.
21.
GattaLLScarpignatoC. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther2017; 45(5): 604–616.
22.
García-CollinotGGMadrigal-SantillánEOMartínez-BencomoMA, et al. Effectiveness of Saccharomyces boulardii and Metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig Dis Sci2020; 65(4): 1134–1143.
23.
AhujaNKNKMischeLClarkeJO, et al. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis. Semin Arthritis Rheum2018; 48(1): 111–116.
24.
VigoneBCaronniMSeverinoA, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS Study. Arthritis Res Ther2017; 19(1): 145.
25.
ShreinerABMurrayCDentonC, et al. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord2016; 1(3): 247–256.
26.
FretheimHHChungBKDidriksenH, et al. Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial. PLoS ONE2020; 15(5): e0232739.
